$PTLA News
Last published 4y ago
- 4y agoPTLAFrazier Life Sciences Adds Highly Experienced Biopharmaceutical Executive to TeamBusiness WireFrazier Life Sciences announced the addition of Tao Fu as a Venture Partner. He has over 25 years of business development, general management, operations, strategy, and commercial leadership experience in the pharmaceutical and biotech industry. Mr.
- 6y agoPTLAApproval of Bevyxxa, Nda #208383 (Labeling)FDA Approved DrugsApproval Date: 08/24/2020; Drug Name: Bevyxxa, Nda #208383; Active Ingredients: BETRIXABAN; Company: Portola Pharms Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 208383
- 6y agoALXNPTLAAlexion Completes Acquisition of PortolaBusiness WireBOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor reversal agent Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya® in Europe, to Alexion’s commercial portfolio. Andexxa is the first and only ap ...
- 6y agoPTLANew patent application published for: Preparation of Factor Xa DerivativesUS Patent Applications (USPTO)
- 6y agoPTLAPortola Pharmaceuticals Announces Virtual 2020 Annual Stockholder MeetingPR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to...
- 6y agoPTLAU.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third YearPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New...
- 6y agoPTLAALXNPortola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate UpdatePR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate...
- 6y agoPTLAALXNPortola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by AlexionPR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) (the "Company" or "Portola") today announced that it is cancelling its webcast and conference call to...
- 6y agoTORCSTMLKLXEPTLAMoore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoALXNPTLAAlexion to Acquire PortolaBusiness WireBOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Portola’s commercialized medicine, Andexxa® [coag ...
- 6y agoPTLAPortola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on April 30, 2020, the Compensation Committee of the Board of Directors approved,...
- 6y agoPTLAPortola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial...
- 6y agoPTLAPortola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that the Centers for Medicare & Medicaid Services (CMS) established a new permanent...
- 6y agoPTLAPortola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on March 31, 2020, the Compensation Committee of the Board of Directors approved,...
- 6y agoPTLAPortola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public heath efforts to prevent...
- 6y agoPTLAPortola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related BleedsPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa® [coagulation factor Xa (recombinant),...
- 6y agoAESAEPPTLANIO+3Cramer's lightning round: First Horizon is doing 'remarkably well'CNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 6y agoPTLANew Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa InhibitorsPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of new data demonstrating that using Andexxa® [coagulation factor Xa...
- 6y agoPTLAPortola Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate UpdatePR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the fourth quarter and full year ended December 31, 2019. "2019...
- 6y agoPTLAPortola Pharmaceuticals to Participate in Two Upcoming Investor ConferencesPR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that the Company will participate in the following conferences in March. Cowen 40th...
- 6y agoPTLAPortola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial...
- 6y agoPTLAPortola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical OfficerPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Rajiv Patni, M.D., as executive vice president and chief medical...
- 6y agoPTLAPTLA LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of its Investigation into Portola Pharmaceuticals, Inc., and Encourages Investors with Losses to Contact the FirmPR NewswireBernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of...
- 6y agoPTLAPortola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 MillionPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced preliminary unaudited Andexxa global net revenues for the fourth quarter and full year...
- 6y agoPTLAPortola Pharmaceuticals to Webcast Corporate Update on January 14, 2020PR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host an investor event to discuss expected corporate and product...
- 6y agoPTLAPortola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic StrokePR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its support of the American Heart Association®/American Stroke Association's® newest...
- 6y agoPTLAPortola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular LymphomaPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an...
- 6y agoPTLAPortola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell MalignanciesPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an...
- 6y agoPTLAAndexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency PhysiciansPR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency...
- 7y agoPTLAPortola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual MeetingPR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an...
- 7y agoPTLAPortola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate UpdatePR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a...
- 7y agoPTLAPortola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors...
- 7y agoPTLAPortola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal BleedingPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new exploratory analysis of data from ANNEXA-4, the Company's...
- 7y agoPTLAPortola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial...
- 7y agoPTLAPortola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of DirectorsPR NewswirePortola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a...
- 7y agoPTLAPortola Pharmaceuticals to Participate in Two Upcoming Investor ConferencesPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following conferences in September. Citi's...
- 7y agoPTLAPortola Pharmaceuticals Announces Pricing of Public Offering of Common StockPR NewswirePortola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock...
- 7y agoPTLAPortola Pharmaceuticals Announces Proposed Offering of Common StockPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced plans to offer, subject to market and other conditions, $200 million of its common...
- 7y agoPTLAPortola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdatePR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2019, and provided a corporate...
- 7y agoPTLAPortola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in EuropePR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the Company's first sales of Ondexxya® (andexanet alfa) in Europe. These sales mark the ...
- 7y agoPTLAU.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' AndexxaPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has increased the...
- 7y agoPTLAPortola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019PR NewswirePortola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial...
- 7y agoPTLAPortola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa InhibitorsPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new in vitro data establishing the relationship between concentrations of the direct...
- 7y agoPTLAPortola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular LymphomaPR NewswirePortola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an...
- 7y agoPTLAPortola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoPTLAPortola Pharmaceuticals (PTLA) CEO Scott Garland on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoPTLAPortola Pharmaceuticals' (PTLA) Management on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoPTLAPortola Pharmaceuticals' (PTLA) CEO Bill Lis on CRL from FDA for BLA for AndexXa (Transcript)Earnings Call Transcripts
- 10y agoPTLAPortola Pharmaceuticals' (PTLA) CEO William Lis on Q2 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoPTLAPortola Pharmaceuticals' (PTLA) CEO Bill Lis on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts